St Jude Medical's gross profit for the
three
months ended in Sep. 2016 was $1,004 Mil. St Jude Medical's gross profit for the trailing twelve months (TTM) ended in Sep. 2016 was $3,977 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. St Jude Medical's gross profit for the
three
months ended in Sep. 2016 was $1,004 Mil. St Jude Medical's Revenue for the
three
months ended in Sep. 2016 was $1,499 Mil. Therefore, St Jude Medical's Gross Margin % for the quarter that ended in Sep. 2016 was 66.98%.
St Jude Medical had a gross margin of 66.98% for the quarter that ended in Sep. 2016 => Durable competitive advantage
St Jude Medical Gross Profit Historical Data
The historical data trend for St Jude Medical's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of St Jude Medical's Gross Profit
For the Medical Devices subindustry, St Jude Medical's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
St Jude Medical's Gross Profit Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, St Jude Medical's Gross Profit distribution charts can be found below:
* The bar in red indicates where St Jude Medical's Gross Profit falls into.
St Jude Medical Gross Profit Calculation
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
St Jude Medical's Gross Profit for the fiscal year that ended in Dec. 2015 is calculated as
Gross Profit for the trailing twelve months (TTM) ended in Sep. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $3,977 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
St Jude Medical (NYSE:STJ) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
St Jude Medical had a gross margin of 66.98% for the quarter that ended in Sep. 2016 => Durable competitive advantage
St Jude Medical Gross Profit Related Terms
Thank you for viewing the detailed overview of St Jude Medical's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
St Jude Medical (St Jude Medical) Business Description
St Jude Medical Inc was incorporated in Minnesota in 1976. It develops, manufactures and distributes cardiovascular medical devices for the cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain. The Company's two segments are the Implantable Electronic Systems Division and the Cardiovascular and Ablation Technologies Division. The Company's principal products in each business unit are as follows: Implantable Electronic Systems Division (IESD) - tachycardia implantable cardioverter defibrillator systems (ICDs), bradycardia pacemaker systems (pacemakers) and neurostimulation products (spinal cord and deep brain stimulation devices); and Cardiovascular and Ablation Technologies Division (CATD) - vascular products (vascular closure products, pressure measurement guidewires, optical coherence tomography (OCT) imaging products, vascular plugs and other vascular accessories), structural heart products (heart valve replacement and repair products and structural heart defect devices) and atrial fibrillation (AF) products (electrophysiology (EP) introducers and catheters, cardiac mapping, navigation and recording systems and ablation systems). Implantable Electronic Systems Division (IESD): IESD is focused on the cardiac rhythm management and neuromodulation therapy areas. Cardiac rhythm management devices include ICDs that provide life-saving therapy to patients suffering from lethal heart conditions, such as sudden cardiac arrest; cardiac resynchronization therapy (CRT) devices to save and improve the lives of patients suffering from heart failure (HF); pacemakers to help patients whose hearts beat too slowly or who suffer from other debilitating cardiac arrhythmias; leads (wires that connect devices to the heart) to carry electrical impulses to the heart and provide information from the heart to the device; and programmers and remote monitoring equipment which are used by physicians and healthcare professionals to program is cardiac rhythm management devices and analyze device data to improve patient management. Neuromodulation product offerings provide neurostimulation treatment in which an implantable device delivers electrical current directly to targeted nerve sites. The Company's commercialized neurostimulation therapies include spinal cord stimulation (SCS) for the treatment of chronic pain, deep brain stimulation (DBS) for treating the symptoms of Parkinson's disease and peripheral nerve stimulation (PNS) for the treatment of chronic migraine headache. A neurostimulation system typically consists of four components: a pulse generator that produces the electrical current and is implanted under the patient's skin; implanted leads that carry the electrical impulses to the targeted nerve sites; an external patient remote control that enables the patient to control his or her therapy within prescribed ranges; and an external clinician pro
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STJ has been successfully added to your 